Immunocore Holdings (IMCR) Liabilities and Shareholders Equity (2019 - 2026)

Immunocore Holdings has disclosed Liabilities and Shareholders Equity across 8 years of filings, most recently posting $1.1 billion for Q1 2026.

• Liabilities and Shareholders Equity for Q1 2026 came in at $1.1 billion, up 4.29% year-over-year; the trailing twelve-month figure through Mar 2026 was $4.3 billion (up 4.31% YoY), and the FY2025 annual result was $1.1 billion, up 5.72% from the prior year.
• Liabilities and Shareholders Equity came in at $1.1 billion for Q1 2026 at Immunocore Holdings, roughly flat from $1.1 billion in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $1.1 billion in Q3 2025 to a low of $510.8 million in Q4 2022.
• The 5-year median for Liabilities and Shareholders Equity is $1.0 billion (2025), against an average of $961.1 million.
• Across the five-year window, Liabilities and Shareholders Equity jumped 69.1% in 2024 and gained 1.65% in 2025, its largest moves.
• Immunocore Holdings' Liabilities and Shareholders Equity stood at $510.8 million in 2022, then advanced by 16.87% to $597.0 million in 2023, then surged by 69.1% to $1.0 billion in 2024, then rose by 5.72% to $1.1 billion in 2025, then gained by 0.45% to $1.1 billion in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $1.1 billion (Q1 2026), $1.1 billion (Q4 2025), and $1.1 billion (Q3 2025), per Business Quant data.